About Globus Medical Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.globusmedical.com/
Frequently Asked Questions
What is the 52-week range for GMED?
The 52-week high is $101.4 and the 52-week low is $56.21.
What is the P/E ratio for GMED?
The Price to Earnings (P/E) ratio is 18.66.
What is the dividend yield for GMED?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 11.59%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 17.03%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.57.
Analyst Recommendation Trends
Wall Street analyst consensus for GMED over the last few months:
Latest GMED News
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.
Neogen Stock Rallies 83% YTD: What's Driving the Surge?
NEOG's 83% YTD rally reflects Food Safety momentum, Petrifilm expansion, solutions-based selling and a growing product pipeline.
RBC Capital Maintains Outperform on Globus Medical, Lowers Price Target to $85
RBC Capital analyst Kendall Au maintains Globus Medical (NYSE:GMED) with a Outperform and lowers the price target from $115 to $85.
The Top HealthTech Questions Landing On Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
GMED vs. ITGR: Which Stock Is the Better Value Option?
GMED vs. ITGR: Which Stock Is the Better Value Option?
Should You Continue to Hold IART Stock in Your Portfolio?
Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
Do You Really Understand ISRG Stock's Risk?
Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's specialty distribution, oncology and GLP-1 growth are driving earnings, while drug pricing, margin pressure and policy uncertainty pose challenges.
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
ITGR's $127-a-share KKR deal offers defined cash value, while core franchises face slow new-product adoption.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.
Globus Medical (GMED) Pulls Back Following Recent Weakness, Is The Stock Trading At A Discount?
Globus Medical (GMED) has drawn investor attention after recent price moves left the stock down about 10% over the past month and roughly 5% lower over the past 3 months. Set against that short term pullback, Globus Medical’s 1 year total shareholder return of 32.5% and 3 year total shareholder return of 50.8% point to a very different picture from the recent 1 month share price decline of about 9.9% and 3 month share price drop of roughly 5.4%. This signals that momentum has cooled recently...
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GEHC's record backlog, strong orders and AI-enabled innovations offer growth potential, while inflation and China remain key risks.
2 Reasons to Watch GMED and 1 to Stay Cautious
Over the last six months, Globus Medical’s shares have sunk to $74.94, producing a disappointing 10.3% loss - a stark contrast to the S&P 500’s 21.4% gain. This may have investors wondering how to approach the situation.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Globus Medical (NYSE:GMED) and its peers.
Can This Number Push ISRG Stock Higher?
Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
How Far Could ISRG Stock Bounce From Here?
Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?
BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.
Globus Medical (GMED) Stock May Trade At A Discount On Earnings
Globus Medical has delivered a 45.9% gain over the past three years, even after a weaker recent patch, which puts a spotlight on one simple question. Is the current share price of US$74.08 adequately backed by the orthopedics specialist's earnings power. The 45.9% return over three years leaves existing holders sitting on material gains. The issue now is whether those profits reflect sustainable earnings or just a richer multiple. The business leans on selling spinal implants and related...
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Can Intuitive Surgical Make Up For A Lower Price Per Surgery?
Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.
3 Profitable Stocks on Our Watchlist
Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns and capitalize on new opportunities.
Is ISRG Stock Really As Expensive As It Looks?
Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now
XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
SYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
1 of Wall Street’s Favorite Stocks on Our Watchlist and 2 Facing Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.
What Makes Globus Medical (GMED) a New Strong Buy Stock
Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
GEHC Launches CareIntellect AI Tool to Optimize Hospital Operations
GE HealthCare launches an AI-powered SaaS tool that predicts hospital capacity challenges up to 72 hours ahead and recommends actions to ease bottlenecks.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.
Should Investors Add EYE Stock to Their Portfolios Now?
National Vision's premium-product demand and stronger customer mix support growth, but rising costs and vendor dependence remain key risks for investors.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Top Robotics Stocks to Add to Your Portfolio for Impressive Returns
Robotics is poised for robust long-term growth. Consider NVDA, TER, ZBRA and GMED for potential market dominance across sectors.
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
ISRG is using AI, software, data and advanced instruments to strengthen da Vinci 5 and stay ahead as robotic surgery competition intensifies.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
Here's Why Tenet Healthcare Shares are Attracting Investors Now
THC's shares are gaining on higher-acuity demand, strong commercial revenues and USPI's continued expansion.
GMED vs. ITGR: Which Stock Should Value Investors Buy Now?
GMED vs. ITGR: Which Stock Is the Better Value Option?
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
Should You Continue to Hold ALGN Stock in Your Portfolio?
Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
Get Paid To Wait For ISRG Stock To Go On Sale
Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
New Strong Buy Stocks for September 11th
RCMT, HCSG, BLMN, AGX and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 11, 2026.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.
COO Q3 Earnings Top Estimates, Revenues Miss on Destocking, Stock Down
Cooper Companies' Q3 EPS beats estimates as expense controls offset softer revenues, while U.S. inventory cuts pressure CooperVision and weigh on shares.
Is This the Right Time to Add Neogen Stock to Your Portfolio?
NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies
Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.
Zacks.com featured highlights include Globus Medical, NetApp and Assurant
Globus Medical, NetApp and Assurant stand out for strong projected sales growth as investors navigate renewed Middle East tensions.
How Much Can ISRG Stock Still Move Against You?
Intuitive Surgical (ISRG) has handed its owners a hard year. The stock is down 25% over the trailing twelve months while the S&P 500 returned 19.3%, and it now trades about 41% below its 52-week high. After a fall like that the natural hope is that the big moves are behind you. Options priced a year out say they are not.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.
3 Sales Growth Stocks to Buy Amid Renewed Middle East Tensions
Globus Medical, NetApp and Assurant stand out for sustainable sales growth, strong cash flow and favorable valuation and profitability screens.
New Strong Buy Stocks for September 9th
BP, CRD.B, HCSG, TILE and GMED have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2026.
PACS Expands Florida Footprint With 32-Facility Acquisition
PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System
Globus Medical (NYSE:GMED) announced that its Excelsius3D imaging system has received CE marking for use in the European Union and United Kingdom. The approval allows Globus Medical to begin commercial launch of the Excelsius3D system across these markets. Excelsius3D is part of Globus Medical's broader imaging and navigation platform for spine and orthopedic procedures. For readers interested in more ways to get exposure to surgical imaging, guidance and automation trends, explore 36...
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
Globus Medical’s Excelsius3D imaging system receives CE mark
The Excelsius3D system is a mobile imaging platform combining 3D CT, 2D fluoroscopy, and digital radiography.
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System
Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European UnionAUDUBON, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that the Excelsius3D™ intelligent 3-in-1 imaging system is now CE marked for commercial sale in the European Union and the United Kingdom. The addition of Excelsius3D™ expands the company’s Excelsius™ Ecosystem of enabling technologies and further enhance
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.
Globus Medical Receives CE Mark For Its Excelsius3D Imaging System For Commercial Sale In EU, U.K.
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that the Excelsius3D™ intelligent 3-in-1 imaging system is now CE marked for commercial sale in the European Union and the
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
1 Growth Stock to Stash and 2 We Turn Down
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | TOBIN JAMES R | -15,000 | - | - |
| 2026-09-15 | TOBIN JAMES R | -15,000 | - | - |
| 2026-09-15 | TOBIN JAMES R | -30,000 | $74.5834 | $2,237,502 |
| 2026-09-15 | TOBIN JAMES R | +15,000 | $63.68 | $955,200 |
| 2026-09-15 | TOBIN JAMES R | +15,000 | $53.75 | $806,250 |
| 2026-08-18 | ZARRILLI STEPHEN T | -25,000 | - | - |
| 2026-08-18 | ZARRILLI STEPHEN T | -25,000 | $87.0386 | $2,175,965 |
| 2026-08-18 | ZARRILLI STEPHEN T | +25,000 | $53.27 | $1,331,750 |
| 2026-07-27 | Davidar David D | -2,500 | - | - |
| 2026-06-05 | Davidar David D | -25,000 | - | - |
| 2026-06-05 | Davidar David D | -25,000 | $80.7629 | $2,019,073 |
| 2026-06-05 | Davidar David D | +25,000 | $26.27 | $656,750 |
| 2026-06-04 | RHOADS ANN D | -25,000 | - | - |
| 2026-06-04 | RHOADS ANN D | +25,000 | $26.27 | $656,750 |
| 2026-02-25 | Huller Kelly | -20,000 | - | - |
| 2026-02-25 | Huller Kelly | -20,000 | $94.5 | $1,890,000 |
| 2026-02-25 | Huller Kelly | +20,000 | $43.58 | $871,600 |
| 2026-02-12 | Huller Kelly | -10,000 | - | - |
| 2026-02-12 | Huller Kelly | -10,000 | $87.67 | $876,700 |
| 2026-02-12 | Huller Kelly | +10,000 | $45.64 | $456,400 |
| 2026-01-21 | Norwalk Leslie V | +15,000 | - | - |
| 2026-01-21 | Pfeil Keith W | +100,000 | - | - |
| 2026-01-21 | Kline Kyle | +30,000 | - | - |
| 2026-01-21 | Paul David C | +100,000 | - | - |
| 2026-01-21 | Douglas Robert Andrew | +15,000 | - | - |
| 2026-01-21 | Lemaitre Dan | +15,000 | - | - |
| 2026-01-21 | RHOADS ANN D | +15,000 | - | - |
| 2026-01-21 | DeFord John A | +15,000 | - | - |
| 2026-01-21 | Wolterman Dan | +15,000 | - | - |
| 2026-01-21 | Davidar David D | +15,000 | - | - |
| 2026-01-21 | Huller Kelly | +40,000 | - | - |
| 2026-01-21 | ZARRILLI STEPHEN T | +15,000 | - | - |
| 2026-01-21 | TOBIN JAMES R | +15,000 | - | - |
| 2026-01-08 | Kline Kyle | -3,594 | - | - |
| 2026-01-08 | Kline Kyle | -3,594 | $101.1 | $363,353 |
| 2026-01-08 | Kline Kyle | +3,594 | $51.87 | $186,421 |
| 2026-01-08 | Norwalk Leslie V | -2,000 | $101.1 | $202,200 |
| 2025-12-12 | Norwalk Leslie V | -4,000 | $88.85 | $355,400 |
| 2025-12-08 | Paul David C | -34,375 | - | - |
| 2025-12-08 | Paul David C | +34,375 | $25.52 | $877,250 |
| 2025-12-01 | Kline Kyle | -4,896 | - | - |
| 2025-12-01 | Kline Kyle | -5,000 | - | - |
| 2025-12-01 | Kline Kyle | -5,000 | - | - |
| 2025-12-01 | Kline Kyle | -5,000 | - | - |
| 2025-12-01 | Kline Kyle | -3,646 | - | - |
| 2025-12-01 | Kline Kyle | -18,542 | $90 | $1,668,780 |
| 2025-12-01 | Kline Kyle | +4,896 | $63.68 | $311,777 |
| 2025-12-01 | Kline Kyle | +5,000 | $64.44 | $322,200 |
| 2025-12-01 | Kline Kyle | +5,000 | $56.43 | $282,150 |
| 2025-12-01 | Kline Kyle | +3,646 | $53.14 | $193,748 |
| 2025-11-25 | Huller Kelly | -7,500 | - | - |
| 2025-11-25 | Huller Kelly | -7,500 | $90 | $675,000 |
| 2025-11-25 | Huller Kelly | +7,500 | $25.96 | $194,700 |
| 2025-11-12 | Davidar David D | -25,000 | - | - |
| 2025-11-12 | Davidar David D | -25,000 | $86.0002 | $2,150,005 |
| 2025-11-12 | Davidar David D | +25,000 | $25.52 | $638,000 |
| 2025-11-11 | ZARRILLI STEPHEN T | -25,000 | - | - |
| 2025-11-11 | ZARRILLI STEPHEN T | -25,000 | $84.2903 | $2,107,258 |
| 2025-11-11 | ZARRILLI STEPHEN T | +25,000 | $44.14 | $1,103,500 |
| 2025-11-10 | RHOADS ANN D | -2,000 | $85 | $170,000 |
| 2025-11-07 | RHOADS ANN D | -8,000 | $81 | $648,000 |